Paul M. Kinsella

Experience

Matters include representation of:

• Wright Medical N.V. in its pending sale to Stryker ($5.4 billion); in its merger with Tornier ($3.3 billion); in $1.5 billion in convertible note and primary and secondary equity offerings; and in disclosure and governance matters
• CIRCOR in its defense of an unsolicited bid by Crane 
• TESARO in its sale to GSK ($5.1 billion)
• NxStage in its sale to Fresenius ($2.0 billion)
• TransMedics in its IPO and in disclosure and governance matters
• Sarepta in $2.5 billion in equity and convertible note offerings and in disclosure matters.
• Novavax in $1.2 billion in equity and convertible note offerings; in its acquisition of Isconova AB; and in disclosure and governance matters 
• The lead underwriters in the Elanco Animal Health IPO ($1.7 billion) and the dealer managers in the exchange of Elanco stock for Lilly stock ($8.6 billion)
• Ironwood in its IPO; in its spin-off of Cyclerion; in $1.3 billion in equity and convertible note offerings; and in disclosure, shareholder activism, and governance matters 
• Pfizer in its acquisition of Medivation ($14 billion), which prevailed in an auction trigged by an unsolicited bid from Sanofi; in its acquisition of Hospira ($17 billion); and in disclosure matters
• Shire in its acquisition of Baxalta ($32 billion and commencing with an unsolicited public proposal shortly following Baxalta’s separation from Baxter) and in its acquisition of Dyax ($5.9 billion)
• Synageva in its sale to Alexion ($8.9 billion); in $2.0 billion in equity offerings; and in disclosure and governance matters
• Cubist in its sale to Merck ($9.5 billion); in its acquisitions of Trius, Optimer, and Adolor, each for a combination of cash and contingent value rights; and in disclosure and governance matters
• Genzyme in its sale to Sanofi ($20.1 billion and contingent value rights); in its acquisitions of Bioenvision, AnorMED (unsolicited tender offer), Bone Care, ILEX ($1.1 billion), SangSat, Focal, GelTex ($1.3 billion) and Biomatrix; and in shareholder activism, disclosure and governance matters
• Javelin in its sale to Hospira, in which Hospira topped a merger agreement with Myriad
• Biomimetic in its sale to Wright Medical for a combination of cash, stock, and contingent value rights
• Zoetis in the exchange of Zoetis stock ($12.9 billion) for Pfizer stock to split-off Zoetis from Pfizer